SCHEMBL29544495

SCHEMBL29544495

CC(C)(C)OC(=O)Nc1cc2c(-c3nn4c(c3Cl)C(=O)N(C(=O)OC(C)(C)C)CC4)ccnc2cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
AAK1 Q2M2I8 5/20 0.34
TGFBR1 P36897 1/20 0.33
CNR1 P21554 1/20 0.33
CDK9 P50750 3/20 0.33
UCHL1 P09936 1/20 0.33
PIK3CD O00329 1/20 0.33
ABL1 P00519 1/20 0.33
EGFR P00533 1/20 0.33
HCK P08631 1/20 0.33
SRC P12931 1/20 0.33
KDR P35968 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
PIK3CG P48736 1/20 0.33
EPHB4 P54760 1/20 0.33
PRKDC P78527 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29544663 0.86 RIPK3 (0.36) GSK3BDYRK1AAAK1TGFBR1CDK9
SCHEMBL29545531 0.83 TYK2 (0.35) TGFBR1CDK9UCHL1EGFRRORC
SCHEMBL29544745 0.73 TYK2 (0.36) TGFBR1CDK9ABL1IRAK4RORC
SCHEMBL29544758 0.71 EGFR (0.39) TGFBR1CDK9EGFRRORCCCNT1
SCHEMBL29544697 0.69 GSK3B (0.44) GSK3BDYRK1ACDK9PIK3CDABL1
SCHEMBL2208824 0.67 AAK1 (0.40) GSK3BDYRK1AAAK1TGFBR1CDK9
SCHEMBL29840658 0.64 ATR (0.52) GSK3BDYRK1AEGFRSRCIRAK4
SCHEMBL437390 0.64 ATR (0.52) GSK3BDYRK1AEGFRSRCIRAK4
SCHEMBL29545167 0.64 PIK3CA (0.32) GSK3BTGFBR1PIK3CAMTOR
SCHEMBL17129412 0.62 BUB1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022072634-A1 BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-04-07 WO disclosed